key: cord-0852342-0rwm2qqt
authors: Chaudhary, Rahul; Padrnos, Leslie; Wysokinska, Ewa; Pruthi, Rajiv; Misra, Sanjay; Sridharan, Meera; Wysokinski, Waldemar; McBane, Robert D.; Houghton, Damon E.
title: Macrovascular Thrombotic Events in a Mayo Clinic Enterprise-wide Sample of Hospitalized COVID-19 Positive Compared to Negative Patients
date: 2021-05-04
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.04.022
sha: 4fdbefeaf0d7d163714f41db8cc169bff9d130dc
doc_id: 852342
cord_uid: 0rwm2qqt

Objective To determine the difference in the rate of thromboembolic complications between hospitalized COVID-19 positive compared COVID-19 negative patients. Methods Adult hospitalized patients with COVID-19 testing by PCR assay were identified through electronic health records across multiple hospitals in the Mayo Clinic Enterprise from 1/1/2020 through 5/8/2020. Thrombotic outcomes (venous and arterial) were identified from the hospital problem list. Results 3,790 hospitalized patients with COVID-19 testing were identified across 19 hospitals, among which 102 tested positive. The median age was lower in the COVID-positive patients (62 vs. 67, p=.02). The median length of hospitalization was longer in COVID-positive patients (9 vs. 4 days, p<.001) and more required ICU care (57.1% vs. 26.7%, p<.001). Comorbidities, including atrial fibrillation/flutter, heart failure, chronic kidney disease, and malignancy were observed less frequently with COVID-positive admissions. Any VTE was identified in 2.9% of COVID-positive and 4.6% of COVID-negative patients (p=.41). The frequency of venous and arterial events was not different between the groups. The unadjusted OR for COVID-positive patients for any VTE was 0.63 (95% CI 0.19-2.02). A multivariable logistic regression model evaluated death within 30 days of hospital discharge; neither COVID-positivity (aOR 1.02, 95% CI 0.49-2.11) nor thromboembolism (aOR 0.90, 95% CI 0.60-1.32) was associated with death. Conclusion Early experience with COVID-19 patients across multiple academic and regional hospitals representing different United States regions demonstrates a lower than previously reported incidence of thrombotic events. This incidence was not higher than a contemporary COVID-negative hospitalized comparator.

COVID-19 pandemic continues to afflict a significant proportion of the population in the world. The rapid addition of literature on the thromboembolic complications associated with COVID-19 has enhanced the understanding of this disease's prothrombotic nature 1, 2 . However, the rates of reported thromboembolic complications have varied from 4% to 69% in COVID-19 patients 3, 4 . The wide range of complications, especially venous thromboembolism (VTE), has led to a debate about the need for aggressive thromboprophylaxis with moderate and higher intensity anticoagulation for patients hospitalized with COVID-19 5, 6 . It needs to be noted that the study populations reporting high rates of thromboembolic complications have lacked adequate control population, include heterogeneous settings (intensive care, ward, ambulatory), inconsistent thromboprophylaxis, inconsistent event detection strategies (clinically driven vs. mandatory), and have a heterogeneous group ranging from Asians, White and Black patients.

From recent literature, we know that ethnicity is an important contributor to intrinsic thrombogenicity, which can affect the frequency of thromboembolic outcomes observed within the study population 7, 8 . In this study, we sought to determine the rate of thromboembolic complications among COVID-19 positive patients compared to those who got tested for COVID-19 but were negative. 

Patient characteristics were identified from clinically recorded data. The problem list (a list of physician-maintained diagnoses from discharge diagnoses) with a separate designation for hospital problems was used to identify comorbid conditions and thromboembolic outcomes. Major and clinically relevant non-major bleeding (CRNMB) was determined by chart review as defined by the International Society for Thrombosis and Haemostasis 9 . As determined by the hospital problem list, bleeding events were not included based on the severity of bleeding by these definitions. Thromboembolic outcomes and anticoagulants type, dosing, and duration used in hospital were also evaluated specifically in COVID-19 positive patients by physician chart review.

Additionally, DVT and PE were evaluated using natural language processing (NLP) from radiology reports occurring immediately before or during admission. All radiology reports of CT scans that included the chest and contained IV contrast and all venous Duplex ultrasounds of the upper or lower extremity were analyzed. NLP algorithms to identify new/acute, or progressive PE and new/acute, or progressive DVT were created, tested, and applied to the text from the radiology report. A separate database of imaging reports (not this cohort) was initially used for algorithm development (PE and DVT). After initial testing, a reiterative approach to algorithm refinement was used, adding additional reports, with subsequent analyses enriched with positive cases as defined by the previous algorithm. This was done to more equally review reports with positive findings since a large majority of reports were negative. A physician reviewed radiology imaging reports from the testing database to make a determination of positive or negative for the finding as defined above. For the DVT algorithm, 1752 lower extremity Duplex ultrasound reports were used in addition to 787 upper extremity Duplex ultrasound reports. The final NLP algorithm for DVT in the lower extremity reports had a 98.2% sensitivity and a 99.6% specificity and for the upper extremity had a 97.8% sensitivity and a 99.2% specificity. The final NLP algorithm for PE correctly identified 325 of 327 reports with PE (as defined above; sensitivity of 99.4%) and 672 out of 673 reports without PE (specificity of 99.9%).

Baseline demographics and clinical features were compared among patient groups:

COVID-19 positive versus COVID-19 negative. Continuous variables were reported as medians and inter-quartile ranges and were compared between groups using the Wilcoxon rank-sum test.

Categorical variables were reported as numbers and percentages and compared between groups using the Chi-square test for independence. The odds ratio of any VTE and any thromboembolic event (composite of arterial and venous thrombosis) was examined by logistic regression based on results from COVID-19 testing. A multivariable logistic regression model with age, sex, BMI, ICU admission, malignancy, diabetes mellitus, atrial fibrillation/flutter, cirrhosis, CKD, atherosclerotic disease, hypertension, congestive heart failure and cirrhosis was then used to examine the odds ratio for any VTE, and thromboembolism based on results from COVID-19 testing. Study data were collected and managed using REDCap (Research Electronic Data Capture), and data analysis was performed using SAS software (SAS Institute Inc., Cary, North Carolina). The Mayo Clinic Institutional Review Board approved the study. Table 1) , and the majority were white. Comorbidities such as atrial fibrillation/flutter, heart failure, chronic kidney disease, and malignancy were all observed less frequently with COVID-positive admissions ( When using NLP to measure outcomes from radiology reports, no significant differences were observed between the COVID-19 positive and negative groups ( Table 2) . Minor discrepancies were noted between the NLP algorithm interpretation of imaging studies and the chart review outcomes. The discrepancies included one PE noted on the problem list which J o u r n a l P r e -p r o o f occurred at an outside hospital before the transfer of the patient and therefore was not captured as an "in-hospital" event by the NLP imaging definition. Additionally, one upper extremity DVT was described as a chronic DVT on the ultrasound, yet due to the presence of an associated central catheter, the treatment team had decided to initiate anticoagulation and was therefore considered to be an "acute DVT" upon chart review.

In this enterprise wide sample of regional and tertiary care hospitals early in the COVID- 

There have been multiple reports demonstrating high rates of thromboembolic complications in COVID-19 patients 4, 12, 13 . The variability in the rate of thromboembolic events noted in multiple studies has led to significant debate regarding the aggressiveness in the thromboprophylaxis regimens among hospitalized COVID-19 patients 5, 6 . However, most studies that report a high rate of thromboembolic complications are in hospitalized patients in the intensive care setting. In our study, the rate of thromboembolic complications in COVID-19 positive patients was 2.9%, which was not significantly different from the COVID-19 negative hospitalized patients. The rate of VTE in the overall population is consistent with the preliminary results from an ongoing prospective registry (CORE-19), where the thromboembolic complications were noted to be 3.51% 14 .

It should be noted that the high-risk factors such as age, body mass index, and comorbidity burden among the COVID-19 positive group in the current study was lower (including atrial fibrillation/flutter, heart failure, atherosclerosis, hypertension, chronic kidney disease, cirrhosis, and malignancy), which could explain the lower rates of complications and better prognosis in this study population. Additionally, although there were significant differences in the racial distribution of patients between the COVID-19 positive and negative populations, overall, the majority of patients were white (88.3%). There have been reports about racial differences in thromboembolic complications and clinical outcomes in COVID-19 patients. White patients have been reported to be at lower risk of poor outcomes than black or Hispanic patients 7, 8 . It is possible that the lower rate of thromboembolic complications in our study was due to the inclusion of a predominantly white population. Our findings reinforce the need for individualized thromboprophylaxis regimens for patients admitted to the hospitals with COVID-19. Compared to the traditionally used risk assessment models (e.g., Padua score), J o u r n a l P r e -p r o o f which do not address the increased risk of thromboembolism in the setting of COVID-19, two possible approaches of personalizing thromboprophylaxis regimens could include 1) assessment of intrinsic thrombogenicity using viscoelastic methods of clot formation 15 , and 2) using Factor Xa levels to guide the intensity of thromboprophylaxis regimens 16 .

The combined methodologies to identify outcomes within the COVID-19 positive and negative groups makes it extremely unlikely that thromboembolic outcome definitions were significantly under-or over-represented. Furthermore, the electronic definitions, even with a finite error rate, helps eliminate assessment bias. Increased imaging within the COVID-19 positive cohort would be anticipated, with a larger number requiring ICU care. If anything, this finding would bias the results toward a higher thromboembolic rate due to the potential to identify incidental thrombotic events. Including all CT scans of the chest that contained contrast in the NLP algorithm to identify PE also helps account for the potential incidental pulmonary embolisms identified. Another strength of this analysis is the study design and inclusion of only patients undergoing COVID-19 testing during associated hospital admission. This helps to create similar cohorts for comparison as patients with COVID-19 positive testing as an outpatient who are struggling with the illness for days or weeks preceding the hospitalization may be likely to have a higher baseline thrombotic risk than patients presenting more acutely due to the preceding inflammatory state and immobility. Also, selecting a control population that also had testing and was known to be negative helps reduce unmeasured confounding between the groups and provide the most accurate control population. Some patients with COVID-19 might have gone unrecognized early in the pandemic. Another possible source of bias in other studies from large J o u r n a l P r e -p r o o f academic medical centers is referral bias. Although this cohort did include patients from tertiary referral centers, it also included numerous smaller regional hospitals that likely better reflect the population as a whole.

Despite attempts to create more similar patients' cohorts for comparison, we did see significant differences in underlying comorbidities between the groups. As expected, patients who required hospitalization in the absence of COVID-19 positive testing had a higher degree of comorbid disease, which could not be fully adjusted for in multivariable analyses due to the sample size and low event rate. However, when considering whether anticoagulation should be used at higher than prophylactic doses, assessing these event rates in an unadjusted comparison can be helpful. Another important consideration in the data presented is that no formal or enterprise-wide algorithm was in place during the study period for either anticoagulation management or serial assessment for thromboembolic events. This helps reduce bias that may have occurred in other observational studies from increased testing and screening of COVID-19 positive patients. Additionally, the readmission group was excluded by the design of the current study and therefore we may have missed quite a few VTEs in COVID-19 positive patients that occurred at a later stage of the disease and future studies should investigate VTE events more broadly.

Early experience with COVID-19 patients across multiple academic and regional hospitals representing different regions of the United States demonstrates a lower than previously reported incidence of thrombotic events in a high-risk cohort, which is not significantly higher than COVID-19 negative hospitalized patients. Although some COVID-19 positive patients may J o u r n a l P r e -p r o o f be at very high risk for thromboembolism, further risk classification strategies are needed to identify these patients better. Our data do not support a more aggressive anticoagulation regimen for all hospitalized COVID-19 patients. We recommend a more conservative/cautious approach until clinical trials demonstrate the benefit of higher intensity anticoagulation regimens. .21 Any thromboembolism, n (%) 6 (5.9) 375 (10) .16 Any bleeding, n (%) 3 (2.9) 259 (7.0) .11

Time to death (from COVID test) in days, median (IQR) 6 (4.5-19.5) 13 (5.5-26.5) .33 Death (inpatient) , n (%) 6 (5.9) 107 (2.9) .08 Death (30 day) , n (%) 9 (8.9) 267 (7. 

COVID-19 Associated Thrombosis and Coagulopathy: Review of the Pathophysiology and Implications for Antithrombotic Management

Identification of key signaling pathways induced by SARS-CoV2 that underlie thrombosis and vascular injury in COVID-19 patients

Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease

Thromboembolic Outcomes of Hospitalized COVID-19 Patients in the 90-Day Post-Discharge Period: Early Data from the Northwell CORE-19 Registry

Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry

Thromboprophylaxis in COVID-19: Anti-FXa-the Missing Factor?

History of VTE, n (%) 3